{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:00:35Z","timestamp":1791475235305,"version":"4.3.4"},"reference-count":153,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Women's Health"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:p>Postmenopausal osteoporosis is an asymptomatic skeletal disease that is often underdiagnosed and undertreated. Osteoporotic fractures are associated with substantial morbidity and mortality and impaired quality of life\u2014socially, emotionally, and financially. Considering the growing burden of osteoporotic fractures worldwide, there remains an ongoing need for progress in the diagnosis of osteoporosis, identification of individuals at high fracture risk, and treatment to prevent fractures. Adequate intake of calcium and vitamin D is recommended as baseline therapy for osteoporosis prevention and treatment. Available pharmacological agents for the management of postmenopausal osteoporosis may not be appropriate for all women. Oral bisphosphonates are generally considered first-line therapy for patients with osteoporosis, but their use may be limited by gastrointestinal side effects. Other agents include hormone therapy, the selective estrogen receptor modulator (SERM) raloxifene, salmon calcitonin, teriparatide (human recombinant parathyroid hormone), and strontium ranelate (in some countries). Factors that may contribute to poor compliance and persistence with current osteoporosis therapies include drug intolerance, complexity of dosing regimens, and poor understanding of the relative benefit and risk with treatment. Emerging therapies for postmenopausal osteoporosis include novel SERMs (bazedoxifene, lasofoxifene, ospemifene, arzoxifene) and denosumab. Because SERMs can display mixed functional estrogen receptor agonist or antagonist activity depending on the target tissue, they may confer beneficial effects on bone with limited stimulation of other tissues (e.g., breast, endometrium). Clinical investigation of these promising new agents is ongoing to evaluate efficacy and safety, with the goal of developing effective strategies to maximize long-term tolerance, compliance, and persistence with therapy.<\/jats:p>","DOI":"10.1089\/jwh.2008.1086","type":"journal-article","created":{"date-parts":[[2009,10,26]],"date-time":"2009-10-26T11:36:49Z","timestamp":1256557009000},"page":"1615-1626","source":"Crossref","is-referenced-by-count":40,"title":["Current and Emerging Pharmacologic Therapies for the Management of Postmenopausal Osteoporosis"],"prefix":"10.1177","volume":"18","author":[{"given":"E. Michael","family":"Lewiecki","sequence":"first","affiliation":[{"name":"University of New Mexico School of Medicine","place":["New Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2009,10,1]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"crossref","unstructured":"North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause 2006; 13:340\u2013367.","DOI":"10.1097\/01.gme.0000222475.93345.b3"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00776-006-1050-9"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-004-1680-8"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.smj.0000221637.90495.66"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030501"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000063449"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1997.12.11.1761"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-007-0340-1"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-004-1702-6"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1997.12.1.16"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1568"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2004.tb05908.x"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.041214"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.rhu.0000158545.26370.5c"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/8756-3282(95)00258-4"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.blo.0000200248.34876.fe"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.3.320"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2000.15.4.721"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001980050063"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200111)44:11<2611::AID-ART441>3.0.CO;2-N"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-3-78"},{"key":"e_1_3_3_23_2","first-page":"140","article-title":"Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and\/or prevalent vertebral fracture: Results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study","volume":"34","author":"Silverman SL","year":"2007","unstructured":"Silverman SL, , Shen W, , Minshall ME, , Xie S, , Moses KH. Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and\/or prevalent vertebral fracture: Results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. J Rheumatol, 2007; 34:140\u2013144.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001980070075"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a116756"},{"key":"e_1_3_3_26_2","unstructured":"World Health Organization Collaborating Centre for Metabolic Bone Diseases. FRAX\u2122 WHO Fracture Risk Assessment Tool. www.shef.ac.uk\/FRAX\/. 2008 March 1."},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-007-0543-5"},{"key":"e_1_3_3_28_2","unstructured":"National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. www.nof.org\/professionals\/Clinicians_Guide.htm. 2008 December 9."},{"key":"e_1_3_3_29_2","first-page":"575","article-title":"Prevention, diagnosis, and management of osteoporosis-related fracture: A multifactorial osteopathic approach","volume":"108","author":"Gronholz MJ","year":"2008","unstructured":"Gronholz MJ. Prevention, diagnosis, and management of osteoporosis-related fracture: A multifactorial osteopathic approach. J Am Osteopath Assoc, 2008; 108:575\u2013585.","journal-title":"J Am Osteopath Assoc"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-996-0028-z"},{"key":"e_1_3_3_31_2","unstructured":"National Osteoporosis Foundation. Scientific statement: Updated recommendations for calcium and vitamin D intake. www.nof.org\/prevention\/calcium_and_VitaminD.htm. 2007 November 18."},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199009273231305"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709043371003"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001980200023"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055218"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)63013-9"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.330.7498.1003"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61342-7"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.16.1999"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2003.18.2.343"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2000.15.6.1113"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/85.6.1586"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.11.6953"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629120-00005"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030897"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.14.1344"},{"key":"e_1_3_3_47_2","first-page":"77","article-title":"Differences between the bisphosphonates for the prevention and treatment of osteoporosis","volume":"2","author":"Grey A","year":"2006","unstructured":"Grey A, , Reid IR. Differences between the bisphosphonates for the prevention and treatment of osteoporosis. Ther Clin Risk Manag, 2006; 2:77\u201386.","journal-title":"Ther Clin Risk Manag"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.040325"},{"key":"e_1_3_3_49_2","first-page":"CD004523","article-title":"Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women","author":"Wells G","year":"2008","unstructured":"Wells G, , Cranney A, , Peterson J et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev, 2008; CD004523.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_50_2","first-page":"CD001155","article-title":"Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women","author":"Wells GA","year":"2008","unstructured":"Wells GA, , Cranney A, , Peterson J et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev, 2008; CD001155.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_51_2","unstructured":"FOSAMAX\u00ae (alendronate sodium) tablets and oral solution [package insert]. Whitehouse Station NJ: Merck & Co. 2007."},{"key":"e_1_3_3_52_2","unstructured":"ACTONEL\u00ae (risedronate sodium tablets) [package insert]. Cincinnati OH: Proctor & Gamble Pharmaceuticals 2007."},{"key":"e_1_3_3_53_2","unstructured":"BONIVA\u00ae (ibandronate sodium) tablets [package insert]. Nutley NJ: Roche Pharmaceuticals 2006."},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-006-0322-8"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-002-2011-8"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.044958"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2008.02010.x"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-006-0735-7"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011807"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21918"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.14.1701"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-1-199501010-00002"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.13.1729"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-11-200212030-00008"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.3.321"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.1.49"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.1.58"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-006-0187-x"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.8.8750"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.7.637"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-005-2030-1"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.040406"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062462"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.23.joc60074"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.108.518621"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1097\/01720610-200612000-00006"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(00)00490-3"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002239900076"},{"key":"e_1_3_3_79_2","unstructured":"MIACALCIN\u00ae (calcitonin-salmon) nasal spray [package insert]. Huningue France: Novartis Pharma S.A.S. 2006."},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200105103441904"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-020334"},{"key":"e_1_3_3_82_2","unstructured":"FORTEO\u2122 teriparatide (rDNA origin) injection 750\u2009mcg\/3\u2009mL [package insert]. Indianapolis IN: Eli Lilly 2007."},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2004-0006"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpendmet0316"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002230010055"},{"key":"e_1_3_3_86_2","first-page":"2060","article-title":"Strontium ran-elate: Dose-dependent effects in established postmenopausal vertebral osteoporosis\u2014A 2-year randomized placebo controlled trial","volume":"87","author":"Meunier PJ","year":"2002","unstructured":"Meunier PJ, , Slosman DO, , Delmas PD et al. Strontium ran-elate: Dose-dependent effects in established postmenopausal vertebral osteoporosis\u2014A 2-year randomized placebo controlled trial. J Clin Endocrinol Metab, 2002; 87:2060\u20132066.","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-002-1349-0"},{"key":"e_1_3_3_88_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1774"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022436"},{"key":"e_1_3_3_90_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200724010-00003"},{"key":"e_1_3_3_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.10.013"},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(04)90023-9"},{"key":"e_1_3_3_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.12.018"},{"key":"e_1_3_3_94_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-008-0021-x"},{"key":"e_1_3_3_95_2","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S2502"},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-007-0466-1"},{"key":"e_1_3_3_97_2","doi-asserted-by":"publisher","DOI":"10.4065\/81.8.1013"},{"key":"e_1_3_3_98_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X167615"},{"key":"e_1_3_3_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2004.02.005"},{"key":"e_1_3_3_100_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38875.675486.55"},{"key":"e_1_3_3_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.01.002"},{"key":"e_1_3_3_102_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730090-00003"},{"key":"e_1_3_3_103_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.20.2414"},{"key":"e_1_3_3_104_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.0707onj"},{"key":"e_1_3_3_105_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2007.06.010"},{"key":"e_1_3_3_106_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0928"},{"key":"e_1_3_3_107_2","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM.2008.310"},{"key":"e_1_3_3_108_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2003.18.6.1051"},{"key":"e_1_3_3_109_2","first-page":"2363","article-title":"Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study","volume":"84","author":"Ravn P","year":"1999","unstructured":"Ravn P, , Hosking D, , Thompson D et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab, 1999; 84:2363\u20132368.","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_3_3_110_2","doi-asserted-by":"publisher","DOI":"10.7863\/jum.1999.18.7.503"},{"key":"e_1_3_3_111_2","first-page":"755","article-title":"Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy","volume":"86","author":"Alexandersen P","year":"2001","unstructured":"Alexandersen P, , Riis BJ, , Stakkestad JA, , Delmas PD, , Christiansen C. Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy. J Clin Endocrinol Metab, 2001; 86:755\u2013760.","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_3_3_112_2","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2002.123938"},{"key":"e_1_3_3_113_2","unstructured":"Smith Kline Beecham drops idoxifene for osteoporosis. SCRIP 1999; 2431:21."},{"key":"e_1_3_3_114_2","unstructured":"Novo Nordisk drops levormeloxifene. SCRIP 1998; 2374:18."},{"key":"e_1_3_3_115_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.10.1663"},{"key":"e_1_3_3_116_2","first-page":"1086","article-title":"Bazedoxifene (Wyeth)","volume":"5","author":"Gruber C","year":"2004","unstructured":"Gruber C, , Gruber D. Bazedoxifene (Wyeth) Curr Opin Investig Drugs, 2004; 5:1086\u20131093.","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_3_3_117_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2001.tb04039.x"},{"key":"e_1_3_3_118_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2005-0030"},{"key":"e_1_3_3_119_2","doi-asserted-by":"publisher","DOI":"10.1007\/3-540-34742-9_2"},{"key":"e_1_3_3_120_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000163253.27610.b9"},{"key":"e_1_3_3_121_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.080710"},{"key":"e_1_3_3_122_2","first-page":"S460","article-title":"Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: Results from a 3-year, randomized, placebo- and active-controlled clinical trial","volume":"22","author":"Adachi JD","year":"2007","unstructured":"Adachi JD, , Chesnut CH, , Brown JP et al. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: Results from a 3-year, randomized, placebo- and active-controlled clinical trial. J Bone Miner Res, 2007; 22:S460[Abstract W385].","journal-title":"J Bone Miner Res"},{"key":"e_1_3_3_123_2","unstructured":"Archer DF Pinkerton JV Utian W et al. Bazedoxifene a selective estrogen receptor modulator: Effects on the endo-metrium ovaries and breast from a randomized controlled trial in osteoporotic postmenopausal women [published online ahead of print June 10 2009]Menopause doi:10.1097\/gme.06013e3181a818db."},{"key":"e_1_3_3_124_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.071206"},{"key":"e_1_3_3_125_2","unstructured":"Pinkerton JV Archer DF Utian WH et al. Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis [published online ahead of print June 10 2009]Menopause doi:10.1097\/gme. 0601ze3181a816be."},{"key":"e_1_3_3_126_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo.139.4.5902"},{"key":"e_1_3_3_127_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2003-1481"},{"key":"e_1_3_3_128_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.gme.0000227337.73738.c9"},{"key":"e_1_3_3_129_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.gme.0000227858.50473.69"},{"key":"e_1_3_3_130_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.gme.0000188736.69617.4f"},{"key":"e_1_3_3_131_2","first-page":"81","article-title":"The effects of lasofoxifene on fractures and breast cancer: 3-year results from the PEARL Trial","volume":"23","author":"Cummings SR","year":"2008","unstructured":"Cummings SR, , Eastell R, , Ensrud K et al. The effects of lasofoxifene on fractures and breast cancer: 3-year results from the PEARL Trial. J Bone Miner Res, 2008; 23:81[Abstract 1288].","journal-title":"J Bone Miner Res"},{"key":"e_1_3_3_132_2","first-page":"81","article-title":"The effects of lasofoxifene on bone turnover markers: The PEARL Trial","volume":"23","author":"Eastell R","year":"2008","unstructured":"Eastell R, , Reid DM, , Vukicevic S et al. The effects of lasofoxifene on bone turnover markers: The PEARL Trial. J Bone Miner Res, 2008; 23:81[Abstract 1287].","journal-title":"J Bone Miner Res"},{"key":"e_1_3_3_133_2","unstructured":"Pfizer Inc. FABLYN\u00ae (lasofoxifene tartrate) 0.5\u2009mg tablets. NDA 22-242. Reproductive Health Drugs Advisory Committee Briefing Document September 8 2008 www.fda.gov\/ohrms\/dockets\/ac\/08\/briefing\/2008-4381b102-Pfizer.pdf. 2008 October 27."},{"key":"e_1_3_3_134_2","unstructured":"CORAL: Comparison of raloxifene and lasofoxifene\u2014A randomized blinded study of these drugs and placebo on bone loss. ClinicalTrials.gov Identifier: NCT00163137. www.clinicaltrials.gov\/ct\/show\/NCT00163137?order=3. 2008 April 24."},{"key":"e_1_3_3_135_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo.141.2.7342"},{"key":"e_1_3_3_136_2","doi-asserted-by":"publisher","DOI":"10.1080\/09513590410001672197"},{"key":"e_1_3_3_137_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.GME.0000063609.62485.27"},{"key":"e_1_3_3_138_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-006-0689-9"},{"key":"e_1_3_3_139_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.5992"},{"key":"e_1_3_3_140_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2002.17.12.2256"},{"key":"e_1_3_3_141_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(24)37755-9"},{"key":"e_1_3_3_142_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200724050-00002"},{"key":"e_1_3_3_143_2","unstructured":"U.S. National Institute of Health National Library of Medicine. Effects of arzoxifene on bone mass and the uterus. www.clinicaltrials.gov\/ct2\/show\/NCT00085956. 2008 April 8."},{"key":"e_1_3_3_144_2","unstructured":"Effects of arzoxifene on bone fractures and incidence of breast cancer. ClinicalTrials.gov Identifier: NCT00088010. www.clinicaltrials.gov\/ct\/show\/NCT00088010. 2008 April 8."},{"key":"e_1_3_3_145_2","unstructured":"Study comparing arzoxifene with raloxifene in women after menopause with osteoporosis. ClinicalTrials.gov Identifier: NCT00383422. www.clinicaltrials.gov\/ct\/show\/NCT00383422?order=5. 2008 April 24."},{"key":"e_1_3_3_146_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg368"},{"key":"e_1_3_3_147_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.06.108"},{"key":"e_1_3_3_148_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.7.2002"},{"key":"e_1_3_3_149_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1933"},{"key":"e_1_3_3_150_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044459"},{"key":"e_1_3_3_151_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.070809"},{"key":"e_1_3_3_152_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2008.04.007"},{"key":"e_1_3_3_153_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.0809010"},{"key":"e_1_3_3_154_2","first-page":"516","article-title":"The effects of twice\u2013yearly denosumab on fracture risk in women with osteoporosis","volume":"20","author":"Cummings S","year":"2009","unstructured":"Cummings S, , Zanchetta J, , McClung M et al. The effects of twice\u2013yearly denosumab on fracture risk in women with osteoporosis. Osteoporos Int, 2009; 20:516.","journal-title":"Osteoporos Int"}],"container-title":["Journal of Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jwh.2008.1086","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jwh.2008.1086","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jwh.2008.1086","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T17:30:36Z","timestamp":1777656636000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jwh.2008.1086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":153,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1089\/jwh.2008.1086"],"URL":"https:\/\/doi.org\/10.1089\/jwh.2008.1086","relation":{},"ISSN":["1540-9996","1931-843X"],"issn-type":[{"value":"1540-9996","type":"print"},{"value":"1931-843X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}